Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 11/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 10/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842723 | 1.00 | GNAO1 (0.39) | GNAO1GNAI3GNAI1KCNH2EPHX1 | |
| SCHEMBL4842716 | 1.00 | GNAO1 (0.39) | GNAO1GNAI3GNAI1KCNH2EPHX1 | |
| SCHEMBL22916040 | 0.86 | KCNH2 (0.38) | GNAO1GNAI3GNAI1KCNH2NOS1 | |
| SCHEMBL14828382 | 0.86 | KCNH2 (0.38) | GNAO1GNAI3GNAI1KCNH2NOS1 | |
| SCHEMBL13483787 | 0.86 | KCNH2 (0.38) | GNAO1GNAI3GNAI1KCNH2NOS1 | |
| SCHEMBL15534390 | 0.86 | KCNH2 (0.38) | GNAO1GNAI3GNAI1KCNH2NOS1 | |
| SCHEMBL13483784 | 0.86 | KCNH2 (0.38) | GNAO1GNAI3GNAI1KCNH2NOS1 | |
| SCHEMBL23963007 | 0.83 | GNAO1 (0.40) | GNAO1GNAI3GNAI1EPHX1ALOX5 | |
| SCHEMBL3632801 | 0.81 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL5258982 | 0.81 | CHRM2 (0.31) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | GNAO1 2121/4885GNAI3 1560/4885GNAI1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.